<?xml version='1.0' encoding='utf-8'?>
<document id="18448350"><sentence text="Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent."><entity charOffset="0-7" id="DDI-PubMed.18448350.s1.e0" text="Aspirin" /></sentence><sentence text="The success of coronary artery bypass graft surgery (CABG) depends mainly on the patency of the graft vessels" /><sentence text=" Aortocoronary vein graft disease is comprised of three distinct but interrelated pathological processes: thrombosis, intimal hyperplasia and atherosclerosis" /><sentence text=" Early thrombosis is a major cause of vein graft attrition during the first month after CABG, while during the remainder of the first year, intimal hyperplasia forms a template for subsequent atherogenesis, which thereafter predominates" /><sentence text=" Platelets play a crucial role in the pathophysiology of graft thrombosis and aspirin is the primary antiplatelet drug that has been shown to improve vein graft patency within the first year after CABG"><entity charOffset="78-85" id="DDI-PubMed.18448350.s5.e0" text="aspirin" /></sentence><sentence text=" Nevertheless, a significant number of grafts still occlude in the early postoperative period despite 'appropriate' aspirin treatment"><entity charOffset="116-123" id="DDI-PubMed.18448350.s6.e0" text="aspirin" /></sentence><sentence text=" Moreover, laboratory investigations showed that the expected inhibition of platelet function is not always achieved" /><sentence text=" This has been called 'aspirin nonresponse' or 'aspirin resistance', although a uniform definition is lacking" /><sentence text=" The finding that a considerable number of patients show an impaired antiplatelet effect of aspirin after CABG brought new insight into the discussion concerning poor patency rates of bypass grafts: the early period after CABG shows a coincidence of an increased risk for bypass thrombosis (amongst others, due to platelet activation and endothelial cell disruption of the graft) and an increased prevalence of aspirin resistance"><entity charOffset="92-99" id="DDI-PubMed.18448350.s9.e0" text="aspirin" /><entity charOffset="106-110" id="DDI-PubMed.18448350.s9.e1" text="CABG" /><entity charOffset="411-418" id="DDI-PubMed.18448350.s9.e2" text="aspirin" /><entity charOffset="222-228" id="DDI-PubMed.18448350.s9.e3" text="CABG" /><pair ddi="false" e1="DDI-PubMed.18448350.s9.e0" e2="DDI-PubMed.18448350.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18448350.s9.e0" e2="DDI-PubMed.18448350.s9.e1" /><pair ddi="true" e1="DDI-PubMed.18448350.s9.e0" e2="DDI-PubMed.18448350.s9.e3" /><pair ddi="true" e1="DDI-PubMed.18448350.s9.e0" e2="DDI-PubMed.18448350.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18448350.s9.e1" e2="DDI-PubMed.18448350.s9.e1" /><pair ddi="true" e1="DDI-PubMed.18448350.s9.e1" e2="DDI-PubMed.18448350.s9.e3" /><pair ddi="true" e1="DDI-PubMed.18448350.s9.e1" e2="DDI-PubMed.18448350.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18448350.s9.e3" e2="DDI-PubMed.18448350.s9.e3" /><pair ddi="false" e1="DDI-PubMed.18448350.s9.e3" e2="DDI-PubMed.18448350.s9.e2" /></sentence><sentence text=" Hitherto, the underlying mechanisms of aspirin resistance are uncertain and largely hypothetical; amongst others, increased platelet turnover, enhanced platelet reactivity, systemic inflammation, and drug-drug interaction are discussed"><entity charOffset="40-47" id="DDI-PubMed.18448350.s10.e0" text="aspirin" /></sentence><sentence text=" Up to now available data concerning the clinical outcome of aspirin resistant CABG patients are limited, and there is evidence that platelets of patients with graft thrombosis are more likely to be resistant to aspirin compared with patients without thrombotic events"><entity charOffset="61-68" id="DDI-PubMed.18448350.s11.e0" text="aspirin" /><entity charOffset="212-219" id="DDI-PubMed.18448350.s11.e1" text="aspirin" /><entity charOffset="79-85" id="DDI-PubMed.18448350.s11.e2" text="CABG" /><pair ddi="false" e1="DDI-PubMed.18448350.s11.e0" e2="DDI-PubMed.18448350.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18448350.s11.e0" e2="DDI-PubMed.18448350.s11.e2" /><pair ddi="false" e1="DDI-PubMed.18448350.s11.e0" e2="DDI-PubMed.18448350.s11.e1" /><pair ddi="false" e1="DDI-PubMed.18448350.s11.e2" e2="DDI-PubMed.18448350.s11.e2" /><pair ddi="false" e1="DDI-PubMed.18448350.s11.e2" e2="DDI-PubMed.18448350.s11.e1" /></sentence><sentence text=" Many publications concerning aspirin resistance are available today, but reports addressing this topic in CABG patients are sparse"><entity charOffset="30-37" id="DDI-PubMed.18448350.s12.e0" text="aspirin" /><entity charOffset="107-113" id="DDI-PubMed.18448350.s12.e1" text="CABG" /><pair ddi="false" e1="DDI-PubMed.18448350.s12.e0" e2="DDI-PubMed.18448350.s12.e0" /><pair ddi="false" e1="DDI-PubMed.18448350.s12.e0" e2="DDI-PubMed.18448350.s12.e1" /></sentence><sentence text=" This review summarises recent insights into the antiplatelet treatment after CABG and describes the clinical benefit, but also the therapeutic failure of the well-established drug aspirin"><entity charOffset="181-188" id="DDI-PubMed.18448350.s13.e0" text="aspirin" /><entity charOffset="78-84" id="DDI-PubMed.18448350.s13.e1" text="CABG" /><pair ddi="false" e1="DDI-PubMed.18448350.s13.e1" e2="DDI-PubMed.18448350.s13.e1" /><pair ddi="false" e1="DDI-PubMed.18448350.s13.e1" e2="DDI-PubMed.18448350.s13.e0" /></sentence><sentence text=" Moreover, possible pharmacological approaches to improve antithrombotic therapy in aspirin nonresponders among CABG patients are discussed"><entity charOffset="84-91" id="DDI-PubMed.18448350.s14.e0" text="aspirin" /><entity charOffset="112-118" id="DDI-PubMed.18448350.s14.e1" text="CABG" /><pair ddi="false" e1="DDI-PubMed.18448350.s14.e0" e2="DDI-PubMed.18448350.s14.e0" /><pair ddi="false" e1="DDI-PubMed.18448350.s14.e0" e2="DDI-PubMed.18448350.s14.e1" /></sentence><sentence text="" /></document>